The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion

– The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price

– Inclisiran, The Medicines Company’s investigational, innovative, potent twice-annual therapy to lower LDL cholesterol, has potential to transform treatment of cardiovascular disease

– Transaction expected to be completed in first quarter of 2020

 

More: https://www.themedicinescompany.com/investor/pr/4241119/